What is the difference between Cabometyx and Cometriq?

Cabometyx (cabozantinib) is taken until disease progression - the cancer starts to get worse - or you can no longer tolerate therapy because of the side effects or adverse reactions.

In clinical trials the median amount of time patients took Cabometyx for before their cancer progressed was:

• METEOR trial - 7.4 months (95% CI 5.6, 9.1)
• CABOSUN trial - 8.6 months (95% CI 6.8, 14.0)
• CELESTIAL trial - 5.2 months (95% CI 4.0, 5.5)
• CHECKMATE-9ER trial - 16.6 months (95% CI 12.5, 24.9)
• COSMIC-311 - 11 months (95% CI 7.4, 13.8)

How successful Cabometyx (cabozantinib) is can be measured by how:

• Long patients take the treatment for
• Long patients survive for without their cancer getting worse (progression-free survival)
• Many months patients remain alive for while taking the treatment
• Many patients respond to the drug

Cabometyx (cabozantinib) is a targeted treatment that targets specific enzymes that are more commonly associated with cancer growth and works differently from traditional chemotherapy agents that kill all cells (both healthy and cancerous) that are in the process of dividing. However, Cabometyx is used to treat cancer, and some people may refer to it as chemotherapy, although a targeted treatment is the more correct term. Continue reading